Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma
Carlos Fernández de Larrea, Mette Stæhr, Andrea V. Lopez, et al.
Blood Cancer Discovery (2020) Vol. 1, Iss. 2, pp. 146-154
Open Access | Times Cited: 171

Showing 1-25 of 171 citing articles:

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
Mehmet Samur, Mariateresa Fulciniti, Anıl Aktaş Samur, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 284
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 254
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
Matteo C. Da Vià, Oliver Dietrich, Marietta Truger, et al.
Nature Medicine (2021) Vol. 27, Iss. 4, pp. 616-619
Closed Access | Times Cited: 226
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients
Mirco Friedrich, Paola Neri, Niklas Kehl, et al.
Cancer Cell (2023) Vol. 41, Iss. 4, pp. 711-725.e6
Open Access | Times Cited: 125
Genetic engineering of T cells for immunotherapy
Gavin I. Ellis, Neil C. Sheppard, James L. Riley
Nature Reviews Genetics (2021) Vol. 22, Iss. 7, pp. 427-447
Open Access | Times Cited: 109
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Gunjan Dagar, Ashna Gupta, Tariq Masoodi, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 104
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia
Mark B. Leick, Harrison Silva, Irene Scarfò, et al.
Cancer Cell (2022) Vol. 40, Iss. 5, pp. 494-508.e5
Open Access | Times Cited: 91
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
Xiaomin Zhang, Hui Zhang, Huixuan Lan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 91
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Mohamad Hamieh, Jorge Mansilla‐Soto, Isabelle Rivière, et al.
Cancer Discovery (2023) Vol. 13, Iss. 4, pp. 829-843
Open Access | Times Cited: 69
Advancing CAR T cell therapy through the use of multidimensional omics data
Jingwen Yang, Yamei Chen, Ying Jing, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 211-228
Closed Access | Times Cited: 65
Anti–G Protein–Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial
Jieyun Xia, Hujun Li, Zhiling Yan, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 14, pp. 2583-2593
Open Access | Times Cited: 61
CAR T therapies in multiple myeloma: unleashing the future
Mohsen Sheykhhasan, Amirhossein Ahmadieh-Yazdi, Rosario Vicidomini, et al.
Cancer Gene Therapy (2024) Vol. 31, Iss. 5, pp. 667-686
Open Access | Times Cited: 49
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Nico Gagelmann, Danai Dima, Maximilian Merz, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 14, pp. 1665-1675
Open Access | Times Cited: 33
Multiple myeloma: signaling pathways and targeted therapy
Qizhong Lu, Donghui Yang, Hexian Li, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 18
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
Dian Zhou, Qian Sun, Jieyun Xia, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 10, pp. e751-e760
Closed Access | Times Cited: 18
Tandem CAR-T cell therapy: recent advances and current challenges
Sara Gómez-Melero, Fakhri Hassouneh, Isabel M. Vallejo-Bermúdez, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 2
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence
Afroditi Katsarou, Maria Sjöstrand, Jyoti Naik, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 623
Open Access | Times Cited: 81
Bispecific Antibodies in Multiple Myeloma: Present and Future
Guido Lancman, Dahniel Sastow, Hearn Jay Cho, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 5, pp. 423-433
Open Access | Times Cited: 76
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
Luis Gerardo Rodríguez‐Lobato, Maya Ganzetti, Carlos Fernández de Larrea, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 73
Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma
Niels W.C.J. van de Donk, Maria Themeli, Saad Z. Usmani
Blood Cancer Discovery (2021) Vol. 2, Iss. 4, pp. 302-318
Open Access | Times Cited: 63
Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MM
Marietta Truger, Johannes Duell, Xiang Zhou, et al.
Blood Advances (2021) Vol. 5, Iss. 19, pp. 3794-3798
Open Access | Times Cited: 61
A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
Chunrui Li, Wenyue Cao, Yimei Que, et al.
Clinical and Translational Medicine (2021) Vol. 11, Iss. 3
Open Access | Times Cited: 57
The EBMT/EHA CAR-T Cell Handbook
Nicolaus Kröger, John G. Gribben, Christian Chabannon, et al.
Springer eBooks (2022)
Closed Access | Times Cited: 57
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
Paula Rodríguez-Márquez, María Eréndira Calleja-Cervantes, Guillermo Serrano, et al.
Science Advances (2022) Vol. 8, Iss. 39
Open Access | Times Cited: 55
Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies
Bailu Xie, Zhengdong Li, Jianfeng Zhou, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3230-3230
Open Access | Times Cited: 50
Page 1 - Next Page

Scroll to top